vs

Side-by-side financial comparison of HF Sinclair Corp (DINO) and Labcorp (LH). Click either name above to swap in a different company.

HF Sinclair Corp is the larger business by last-quarter revenue ($6.5B vs $3.5B, roughly 1.8× Labcorp). Labcorp runs the higher net margin — 4.7% vs -0.4%, a 5.1% gap on every dollar of revenue. On growth, Labcorp posted the faster year-over-year revenue change (5.6% vs -0.6%). Labcorp produced more free cash flow last quarter ($490.3M vs $-123.0M). Over the past eight quarters, Labcorp's revenue compounded faster (5.2% CAGR vs -4.1%).

HF Sinclair Corporation is an American energy company that manufactures and sells products such as gasoline, diesel fuel, jet fuel, renewable diesel, specialty lubricant products, specialty chemicals, and specialty and modified asphalt, among others. It is based in Dallas, Texas, United States.

Labcorp is a leading global life sciences and diagnostic testing firm that offers comprehensive clinical laboratory services, drug development support, and medical testing solutions for healthcare providers, pharmaceutical companies, and individual patients. It uses advanced scientific expertise and innovative technologies to deliver accurate, actionable health insights that support clinical decisions, accelerate new treatment development, and improve patient health outcomes globally.

DINO vs LH — Head-to-Head

Bigger by revenue
DINO
DINO
1.8× larger
DINO
$6.5B
$3.5B
LH
Growing faster (revenue YoY)
LH
LH
+6.2% gap
LH
5.6%
-0.6%
DINO
Higher net margin
LH
LH
5.1% more per $
LH
4.7%
-0.4%
DINO
More free cash flow
LH
LH
$613.3M more FCF
LH
$490.3M
$-123.0M
DINO
Faster 2-yr revenue CAGR
LH
LH
Annualised
LH
5.2%
-4.1%
DINO

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
DINO
DINO
LH
LH
Revenue
$6.5B
$3.5B
Net Profit
$-28.0M
$164.7M
Gross Margin
28.2%
Operating Margin
0.1%
7.6%
Net Margin
-0.4%
4.7%
Revenue YoY
-0.6%
5.6%
Net Profit YoY
86.9%
14.9%
EPS (diluted)
$-0.15
$1.98

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DINO
DINO
LH
LH
Q4 25
$6.5B
$3.5B
Q3 25
$7.3B
$3.6B
Q2 25
$6.8B
$3.5B
Q1 25
$6.4B
$3.3B
Q4 24
$6.5B
$3.3B
Q3 24
$7.2B
$3.3B
Q2 24
$7.8B
$3.2B
Q1 24
$7.0B
$3.2B
Net Profit
DINO
DINO
LH
LH
Q4 25
$-28.0M
$164.7M
Q3 25
$403.0M
$261.1M
Q2 25
$208.0M
$237.9M
Q1 25
$-4.0M
$212.8M
Q4 24
$-213.5M
$143.4M
Q3 24
$-75.9M
$169.3M
Q2 24
$151.8M
$205.3M
Q1 24
$314.7M
$228.0M
Gross Margin
DINO
DINO
LH
LH
Q4 25
28.2%
Q3 25
28.8%
Q2 25
29.7%
Q1 25
28.3%
Q4 24
26.9%
Q3 24
27.6%
Q2 24
28.8%
Q1 24
15.7%
28.2%
Operating Margin
DINO
DINO
LH
LH
Q4 25
0.1%
7.6%
Q3 25
7.8%
11.1%
Q2 25
4.1%
11.2%
Q1 25
1.3%
9.7%
Q4 24
-3.5%
6.5%
Q3 24
-1.7%
7.7%
Q2 24
2.5%
9.2%
Q1 24
5.8%
10.1%
Net Margin
DINO
DINO
LH
LH
Q4 25
-0.4%
4.7%
Q3 25
5.6%
7.3%
Q2 25
3.1%
6.7%
Q1 25
-0.1%
6.4%
Q4 24
-3.3%
4.3%
Q3 24
-1.1%
5.2%
Q2 24
1.9%
6.4%
Q1 24
4.5%
7.2%
EPS (diluted)
DINO
DINO
LH
LH
Q4 25
$-0.15
$1.98
Q3 25
$2.15
$3.12
Q2 25
$1.10
$2.84
Q1 25
$-0.02
$2.52
Q4 24
$-1.05
$1.72
Q3 24
$-0.40
$2.00
Q2 24
$0.79
$2.43
Q1 24
$1.57
$2.69

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DINO
DINO
LH
LH
Cash + ST InvestmentsLiquidity on hand
$978.0M
$532.3M
Total DebtLower is stronger
$2.8B
Stockholders' EquityBook value
$9.2B
$8.6B
Total Assets
$16.5B
$18.4B
Debt / EquityLower = less leverage
0.30×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DINO
DINO
LH
LH
Q4 25
$978.0M
$532.3M
Q3 25
$1.5B
$598.1M
Q2 25
$874.0M
$647.3M
Q1 25
$547.0M
$369.4M
Q4 24
$800.0M
$1.5B
Q3 24
$1.2B
$1.5B
Q2 24
$866.3M
$265.1M
Q1 24
$1.2B
$99.3M
Total Debt
DINO
DINO
LH
LH
Q4 25
$2.8B
Q3 25
$2.8B
Q2 25
$2.7B
Q1 25
$2.7B
Q4 24
$2.6B
Q3 24
Q2 24
Q1 24
Stockholders' Equity
DINO
DINO
LH
LH
Q4 25
$9.2B
$8.6B
Q3 25
$9.4B
$8.7B
Q2 25
$9.3B
$8.5B
Q1 25
$9.2B
$8.3B
Q4 24
$9.3B
$8.1B
Q3 24
$9.6B
$8.2B
Q2 24
$9.9B
$8.0B
Q1 24
$10.2B
$8.0B
Total Assets
DINO
DINO
LH
LH
Q4 25
$16.5B
$18.4B
Q3 25
$17.3B
$18.3B
Q2 25
$16.8B
$18.1B
Q1 25
$16.5B
$17.6B
Q4 24
$16.6B
$18.4B
Q3 24
$16.9B
$18.6B
Q2 24
$17.4B
$16.7B
Q1 24
$17.9B
$16.5B
Debt / Equity
DINO
DINO
LH
LH
Q4 25
0.30×
Q3 25
0.29×
Q2 25
0.29×
Q1 25
0.29×
Q4 24
0.29×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DINO
DINO
LH
LH
Operating Cash FlowLast quarter
$8.0M
$614.2M
Free Cash FlowOCF − Capex
$-123.0M
$490.3M
FCF MarginFCF / Revenue
-1.9%
13.9%
Capex IntensityCapex / Revenue
2.0%
3.5%
Cash ConversionOCF / Net Profit
3.73×
TTM Free Cash FlowTrailing 4 quarters
$866.0M
$1.2B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DINO
DINO
LH
LH
Q4 25
$8.0M
$614.2M
Q3 25
$809.0M
$387.2M
Q2 25
$587.0M
$620.6M
Q1 25
$-89.0M
$18.5M
Q4 24
$-140.4M
$777.2M
Q3 24
$707.6M
$277.3M
Q2 24
$225.9M
$561.1M
Q1 24
$316.9M
$-29.8M
Free Cash Flow
DINO
DINO
LH
LH
Q4 25
$-123.0M
$490.3M
Q3 25
$688.0M
$280.5M
Q2 25
$476.0M
$542.7M
Q1 25
$-175.0M
$-107.5M
Q4 24
$-313.5M
$665.1M
Q3 24
$584.0M
$161.5M
Q2 24
$141.7M
$432.9M
Q1 24
$227.8M
$-163.6M
FCF Margin
DINO
DINO
LH
LH
Q4 25
-1.9%
13.9%
Q3 25
9.5%
7.9%
Q2 25
7.0%
15.4%
Q1 25
-2.7%
-3.2%
Q4 24
-4.8%
20.0%
Q3 24
8.1%
4.9%
Q2 24
1.8%
13.4%
Q1 24
3.2%
-5.2%
Capex Intensity
DINO
DINO
LH
LH
Q4 25
2.0%
3.5%
Q3 25
1.7%
3.0%
Q2 25
1.6%
2.2%
Q1 25
1.4%
3.8%
Q4 24
2.7%
3.4%
Q3 24
1.7%
3.5%
Q2 24
1.1%
4.0%
Q1 24
1.3%
4.2%
Cash Conversion
DINO
DINO
LH
LH
Q4 25
3.73×
Q3 25
2.01×
1.48×
Q2 25
2.82×
2.61×
Q1 25
0.09×
Q4 24
5.42×
Q3 24
1.64×
Q2 24
1.49×
2.73×
Q1 24
1.01×
-0.13×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DINO
DINO

Transportation Fuels$5.0B77%
Lubricants And Specialties Segment$586.0M9%
Lubricants And Specialty Products$531.0M8%
Crude Oil$213.0M3%
Renewables Segment$163.0M3%
Midstream Segment$35.0M1%
Transportation And Logistic Services$34.0M1%

LH
LH

Diagnostics$2.7B78%
Biopharma Laboratory Services$793.0M23%

Related Comparisons